Relavent peges only

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 24 February 2000 (24.02.2000)

PCT

(10) International Publication Number WO 00/09552 A1

- (51) International Patent Classification⁶: C07K 14/435, 14/00, 7/06, C12N 5/10, 15/10, 15/11, 15/12, 15/63, A61K 38/16
- (21) International Application Number: PCT/US99/18298
- (22) International Filing Date: 13 August 1999 (13.08.1999)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/096.622	14 August 1998 (14.08.1998)	US
60/096.815	17 August 1998 (17.08.1998)	US
60/099,229	4 September 1998 (04.09.1998)	US
60/105.368	23 October 1998 (23.10.1998)	US
60/115,234	8 January 1999 (08.01.1999)	US
60/119.931	12 February 1999 (12.02,1999)	US
60/120.575	18 February 1999 (18.02.1999)	US
60/132,020	30 April 1999 (30.04.1999)	US
60/148.424	11 August 1999 (11.08.1999)	US

(71) Applicant: GENETICS INSTITUTE, INC. [US/US]: 87 CambridgePark Drive, Cambridge, MA 02140 (US).

(72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton. MA 02160 (US). McCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LaVALLIE, Edward, R.; 133 Ann Lee Road, Harvard, MA 01451 (US). COLLINS-RACIE, Lisa, A.; 124 School Street, Acton. MA 01720 (US). EVANS, Cheryl; 18801 Bent Willow Circle, Germantown, MA 20874 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice: 12 Foxrock Court, Dublin 4 (IE). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US). STEININGER, Robert, J., II; 100

Reed Street, Cambridge, MA 02140 (US). SPAULDING, Vikki; 11 Meadowbank Road, Billerica, MA 01821 (US). WONG, Gordon, G.; 239 Clark Road, Brookline, MA 02146 (US). CLARK, Hilary, F.; 495 Harkness Avenue. San Francisco, CA 94134 (US). FECHTEL, Kim; 46 Marion Road, Arlington, MA 02174 (US).

- (74) Agents: MANDRAGOURAS, Amy, E. et al.: Lahive & Cockfield, LLP. 28 State Street. Boston. MA 02109 (US).
- (81) Designated States (national): AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
- (84) Designated States (regional): ARIPO patent (GH. GM. KE, LS. MW, SD, SL, SZ, UG, ZW). Eurasian patent (AM. AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT. BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (48) Date of publication of this corrected version: 14 February 2002
- (15) Information about Correction: see PCT Gazette No. 07/2002 of 14 February 2002. Section

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

00/09552 A1

WO 00/09552 PCT/US99/18298

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide endcoing the protein of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, Nucleic Acids Res. <u>19</u>, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology <u>185</u>, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

25

30

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial